Free Trial
OTCMKTS:RCDTF

Recordati Industria Chimica e Farmaceutica (RCDTF) Stock Price, News & Analysis

Recordati Industria Chimica e Farmaceutica logo
$52.25 0.00 (0.00%)
(As of 11/21/2024 ET)

About Recordati Industria Chimica e Farmaceutica Stock (OTCMKTS:RCDTF)

Key Stats

Today's Range
$52.25
$52.25
50-Day Range
$52.25
$52.25
52-Week Range
$52.25
$52.25
Volume
N/A
Average Volume
2 shs
Market Capitalization
N/A
P/E Ratio
26.13
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Reduce

Company Overview

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

Receive RCDTF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Recordati Industria Chimica e Farmaceutica and its competitors with MarketBeat's FREE daily newsletter.

RCDTF Stock News Headlines

Recordati’s Strategic Share Buyback Initiative
Recordati Completes Share Buy-Back Program
What Comes Next Could Be a Once-in-a-Lifetime Opportunity
A wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come.
Recordati Launches Share Buy-Back Program to Boost Incentives
Recordati Enhances Share Value with Buyback Program
Recordati Advances in Share Buyback Program
See More Headlines

RCDTF Stock Analysis - Frequently Asked Questions

Recordati Industria Chimica e Farmaceutica's stock was trading at $46.00 on January 1st, 2024. Since then, RCDTF shares have increased by 13.6% and is now trading at $52.25.
View the best growth stocks for 2024 here
.

Shares of RCDTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Today
11/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Private households
Sub-Industry
N/A
Current Symbol
OTCMKTS:RCDTF
Previous Symbol
NASDAQ:RCDTF
CIK
N/A
Employees
4,455
Year Founded
N/A

Profitability

Net Income
$421.25 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.25 billion
Cash Flow
$3.06 per share
Book Value
$7.90 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.34
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (OTCMKTS:RCDTF) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners